Dopamine receptors in pituitary adenomas: PET visualization with 11C-N-methylspiperone.
Two patients with pituitary tumors were examined with positron emission tomography (PET) after intravenous administration of 11C-N-methylspiperone. In repeat studies the patients were given 1 mg of intravenous haloperidol prior to the administration of the radioligand to block the dopamine receptors. High uptakes of the radiolabeled ligand were seen in one of the tumors. With haloperidol pretreatment the uptake was lower, probably mainly showing the remaining unspecific binding. The most marked uptake and the largest effect of haloperidol pretreatment was seen in a patient with a hormonally active prolactinoma. Dopamine receptor binding in pituitary tumors can be demonstrated in vivo with PET, and quantification of this binding is possible using a compartmental model. This technique may be useful in improving our understanding of the variable response to medical treatment of prolactinomas with dopamine agonists as well as in the prediction of the effect of such treatment.
D000236:Adenoma / Q000000981:diagnostic imaging* / Q000378:metabolism; D000328:Adult; D000368:Aged; D002090:Butyrophenones; D002250:Carbon Radioisotopes; D005260:Female; D006220:Haloperidol; D006801:Humans; D008297:Male; D010911:Pituitary Neoplasms / Q000000981:diagnostic imaging* / Q000378:metabolism; D011388:Prolactin / Q000378:metabolism; D011869:Radioligand Assay / Q000379:methods; D011954:Receptors, Dopamine / Q000032:analysis* / Q000187:drug effects; D013134:Spiperone / Q000031:analogs & derivatives; D014055:Tomography, Emission-Computed / Q000379:methods*
D002090:Butyrophenones; D002250:Carbon Radioisotopes; D011954:Receptors, Dopamine; D013134:Spiperone; C039167:3-N-methylspiperone; D011388:Prolactin; D006220:Haloperidol